At the 2018 ASCO conference, the results of a study on chemotherapy attracted a lot of attention. Studies have shown that an innovative chemotherapy can effectively treat pancreatic cancer known as the “king of cancer”. For this cancer with a very poor prognosis, this chemotherapy can actually prolong the life of the patient for up to 20 months!
Tijaabo caafimaad oo lagu magacaabo PRODIGE 24 / CCTG PA.6, cilmi-baarayaashu waxay qorteen tiro badan oo bukaanno ah oo qaba adenocarcinoma pancreatic duct adenocarcinoma (PDAC), oo sidoo kale ah kansarka ugu badan ee ganaca, oo xisaabiya 90% dhammaan kiisaska. %. Bukaanadan ayaa lagu sameeyay qaliin looga soo saaray burada. Isbuucyada 3-12 ee qaliinka ka dib, wadarta guud ee bukaanada 493 ayaa si aan kala sooc lahayn loo qaybiyay laba kooxood, koox ka mid ah waxay heleen daawaynta gemcitabine (gemcitabine), kooxda kale waxay heleen daawaynta chemotherapy cusub mFOLFIRINOX (la beddelay FOLFIRINOX). Kan dambe waxa uu ka kooban yahay afar qaybood oo kiimiko ah oo kala duwan, oo ay ku jiraan oxaliplatin, leucovorin, irinotecan, iyo 5-fluorouracil.
Daraasadu waxay muujisay in dhexdhexaadinta dhexdhexaadka ah ee bilaha 33.6, badbaadada dhexdhexaadka ah ee bukaan-socodka ee bukaan-socodka ee kooxda mFOLFIRINOX ayaa aad uga sarreeyay kooxda gemcitabine (21.6 bilood-12.8 bilood). Marka la eego badbaadada guud ee dhexdhexaadka ah, kan hore wuu ka sarreeyaa 20kii bilood ee hore (54.4 bilood-35.0 bilood). Faa'iidooyinka badbaadada ee dheeraadka ah, waxyeelada daweynta kemotherabi sidoo kale waa la xakameyn karaa.
Sida qorshuhu yahay, cilmi-baarayaashu waxay sii wadi doonaan inay sahamiyaan waqtiga ugu fiican ee kiimoterabiga si ay u fahmaan in bukaanku heli karo kiimoterabi ka hor qalliinka si loo yareeyo burada, taas oo yaraynaysa khatarta micrometastasis ee buro iyo kordhinta suurtogalnimada in burada gebi ahaanba laga saaro qaliin Waxaan rajeyneynaa inaan maqalno war wanaagsan oo ku saabsan daaweyntan oo aan u oggolaano bukaannada qaba kansarka ganaca inay arkaan rajo.
